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We performed a nested cohort case–control study in which the par-
ticipants were drawn from a cohort of 588 pregnant women followed
from the ﬁrst trimester to delivery in the Centro de Salud Urbano “José
Castro Villagrana” and the Hospital de laMujer Zacatecana, in Zacatecas,
Mexico, between November 2011 and January 2014. The criteria for PE
diagnosis and its severity/onset sub-classiﬁcations were established ac-
cording as described in previous investigations [1,5]. The study exclu-
sion criteria included gestational hypertension, gestational diabetes
mellitus, and underlying medical diseases. All cohort patients providedPreeclampsia (PE) is a pregnancy multisystem disorder that is char-
acterized by hypertension and proteinuria that develops after the 20th
gestational week (GW). The placenta abnormal implantation process
is well known to play a major role in the development of disease [1].
The molecular mechanisms that are involved in normal placental im-
plantation are tightly related to the proliferative and invasive capacity
of trophoblast cells and recent evidence suggests a common conver-
gence between PE genes and those involved in tumor progression
[2–4]. Although the invasion process is increased in cancer and occurs
to a lesser extent in PE, known cancer genes involved in tumor progres-
sion may be useful as potential PE biomarkers and could play a role in
the PE etiopathogenesis. Because to date, no biomarkers have been suc-
cessfully validated for accurate identiﬁcation of patients at risk for therowth factor2;sHER-2/neu,sol-
homolog2; sIL-6Rα, soluble in-
factor binding protein 1; uPA,
I,bodymass index;ROC,receiv-
omenpredictedtodeveloppre-
egative value.
icina Humana y Ciencias de la
atecas-Guadalajara Km.6, Ejido
ez-Fierro).
land Ltd. This is an open access articlPE development, in this study, we evaluate the usefulness of predicting
written informed consent for their participation, and the Institutional
Review Board approvals were obtained (ID: ACS/UAZ.Ofc.No.0042010-
06/2014 and HMZ-117/14). The participants provided peripheral
blood starting on the 12th, 16th and/or 20th GW. Patients who had a
PE diagnosis during the follow-up provided a fourth blood sample at
the time of diagnosis. Sixteen women who developed PE during the
follow-up period were selected and individually matched based onma-
ternal age, null-parity, personal/family histories of PE, and body mass
index (BMI), to 18 women who had healthy pregnancies without com-
plications. A total of 91 plasma samples were obtained, with 22 corre-
sponding to samples donated on 12 GW (6 from women predicted to
develop PE (WPD-PE) and 16 from controls), 23 on 16 GW (8 from
WPD-PE and 15 from controls), 31 on 20 GW (15 from WPD-PE and
16 from controls), and with the remaining 15 being from the WPD-PE
at the time of the PE diagnosis. Cell-free plasma was obtained from
blood samples collected in tubes with EDTA as described previously
[6] and stored at−80 °C until assayed. The plasma measurements of
34 proteins were assayed in duplicate using the Bio-Plex Pro™ Human
Cancer Biomarker Panel 1, and 2 (171-AC500M and 171-AC600M:
Bio-Rad, Hercules, CA, USA) kits, according to the manufacturer's in-
structions using 200-μl of sample. The ﬁnal reaction mixtures were
quantiﬁed using the Bio-Plex MAGPIX® instrument and the data were
processed and analyzed using Bio-Plex Manager Software 6.1 (all Bio-
Rad). Evaluation of simple biomarker comparisons between the WPD-
PE and the controls, and/or according to PE severity or onset of disease,
was performed using Student's t-test or Mann–Whitney rank sum test.e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Kruskal–Wallis oneway analysis of variance on ranks coupled to Dunn's
method as a multiple comparison procedure. The PE predictive capacity
of proposed proteins was evaluated using a Receiver Operating Charac-
teristic curve (ROC) analysis. The odds ratios (OR)with Yates continuity
correctionwere calculated for signiﬁcant comparisons. Statistical analy-
sis was performed considering a signiﬁcance level of 0.05 with the soft-
ware Sigma Plot v.11 (Systat Software Inc., San Jose, CA) and GraphPad
Prism v.5.03 (Graph-Pad Software, San Diego, California, USA).
The 25% of the cases were diagnosed with early PE, and 31% were
subclassiﬁed as severe PE. Fig. 1 shows that, based on the34markers an-
alyzed, three of them at 16 GW (FGF-basic, sHER2/neu, and uPA) and
four at 20 GW (sHER2/neu, sIL-6α, endoglin, and IGFBP-1) had differ-
ences between the WPD-PE and controls (P values b 0.05). Differences
in the plasma concentration of these markers between the severe and
mild PE patients nor between the patients with early and late disease
onset were not observed (P values N 0.05; data not shown). The evalu-
ation of the potential usefulness of the markers identiﬁed to classify
pregnant women by their risk of developing PE (Table 1) showed that,
on an individual basis, FGF-basic and uPA showed a sensitivity of 100%Fig. 1. Concentration data of the signiﬁcant markers at the four pregnancy time points. Pregnan
trations (pg/ml) of eachmarkerwere compared between thegroups at each timepoint. Theﬁgu
For the WPD-PE, a set of 15 samples at the time of the PE diagnosis was included in the plot; tat 16 GW whereas sIL-6Rα showed a sensitivity of 93% at 20 GW. The
best speciﬁcity value (100%) was observed for sHER2/neu at 16 GW. Al-
though the individual markers identiﬁed with high sensitivity values
had low speciﬁcity (in the range of 50–69%) and vice-versa, the concen-
tration cutoff values obtained allowed us to calculate up to 18-fold in-
creased risk for PE development among the study population. The
classiﬁcatory capacity for PE development increased when FGF-basic
and uPA were used together; their ratio allowed us to classify WPD-PE
as early as 16 GW with the lowest values of false negative (0.0%) and
false positive (27%) rates and thereforewith higher sensitivity and spec-
iﬁcity values (100% and 79%, respectively). There are no previous stud-
ies that have evaluated the PE predictive capacity of those proteins
together in maternal plasma during the ﬁrst and second trimesters of
pregnancy and only a few longitudinal reports have evaluated mole-
cules with PE predictive capacity [7–10]. Despite one of the developed
algorithms for the calculation of patient-speciﬁc risk, had acceptable
rates of false-positive (5%), it involves a large combination of variables
(maternal/clinical factors, serum biomarkers and ultrasound measure-
ments) [7] that make the risk determination difﬁcult. This study pro-
poses a new set of biomarkers for PE prediction and suggests thatcies were classiﬁed asWPD-PE or as pregnancies without complications, and the concen-
re shows the results obtained for FGF-basic, sHER2/neu, sIL-6α, uPA, endoglin, and IGFBP-1.
his sample set was not available for the controls.
Table 1
ROC analysis of the signiﬁcant markers.
Parameter 16 GW 20 GW
FGFb sHER2/neu uPA FGFb/uPA sHER2/neu sIL-6Ra Endoglin IGFBP-1
Area under ROC curve 0.82 0.76 0.77 0.86 0.83 0.78 0.73 0.74
Cutoff (pg/ml) 187.4 3798 207.9 0.75 3757 8255 869 34,327
Sensitivity 1 0.500 1 1 0.67 0.93 0.73 0.8
Speciﬁcity 0.67 1 0.67 0.79 0.88 0.56 0.69 0.69
PPV 0.62 1 0.62 0.73 0.83 0.67 0.69 0.69
PNV 1 0.79 1 1 0.74 0.90 0.73 0.73
Odds ratio ND ND ND ND 14.00 18.00 6.10 6.10
95% CI ND ND ND ND 2.3–87.2 1.9–171.9 1.3–28.7 1.3–28.7
P value 0.003* 0.008* 0.003* 0.001* 0.006* 0.006* 0.047* 0.047*
PPV: predictive positive value; PNV: predictive negative value; ROC: receiver operating characteristic; ND: not determined.
60 M.L. Martinez-Fierro et al. / International Journal of Cardiology 179 (2015) 58–60FGF-basic, sHER2/neu sIL-6Rα, endoglin, and IGFBP-1 may be involved
in the pathogenesis of disease. Future longitudinal studieswill be neces-
sary to validate the markers proposed as an early PE screening test.
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